Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Market Outlook and Forecast

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Published Date : 2021-11-20

Updated On : 2023-09-12

Pages : 151

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Outlook

Thelansis’s “Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Blastic Plasmacytoid Dendritic Cell Neoplasm treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Overview

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with an unfavorable prognosis. It predominantly manifests with cutaneous lesions, which are frequently asymptomatic and can range from solitary to multiple, covering a wide area. These skin manifestations can vary from bruise-like discolorations to plaques or nodules. Additionally, patients may exhibit bone marrow involvement, infiltration of the central nervous system (CNS), lymph node enlargement, spleen enlargement, and various degrees of cytopenias. Within the dendritic cell and histiocytic neoplasms category, BPDCN is grouped alongside plasmacytoid dendritic cell proliferation associated with myeloid neoplasms. BPDCN primarily affects older men, with a male-to-female ratio ranging from 3:1 to 5:1, typically diagnosed between 60 and 70. The most common initial clinical presentation of BPDCN involves asymptomatic skin lesions, occurring in approximately 90% of patients at diagnosis. These skin lesions can manifest as areas resembling bruises, patches, plaques, or nodules. While some individuals may exhibit exclusively skin-related symptoms, most also demonstrate BPDCN involvement in the bone marrow, lymph nodes, and visceral organs. In rare instances, patients may present with a leukemic phase of the disease without any apparent skin lesions. CNS involvement is observed in around 30% of patients, and BPDCN can manifest in less common sites such as soft tissues, the breast, gallbladder, tongue, and lung. Some patients may also have concomitant myeloid neoplasms like CMML, MDS, and AML, referred to as prior or concurrent hematologic malignancy (PCHM). Although a small percentage of patients may have isolated skin involvement, most will also have BPDCN detected in the bone marrow, lymph nodes, or visceral organs. Unfortunately, the prognosis for most patients is grim, with a survival period of only 10 to 14 months post-diagnosis, despite receiving various chemotherapy treatments. Allogeneic stem cell transplantation (alloSCT) represents the sole potentially curative treatment option for BPDCN. However, due to the preponderance of this disease in older individuals, only a minority of BPDCN patients are suitable candidates for alloSCT. BPDCN predominantly affects males, with a male-to-female ratio of approximately 3.3:1, typically occurring in the seventh or eighth decade of life.

  • It has an estimated incidence rate of about 0.04 cases per 100,000 individuals, although it can manifest at any age, including childhood.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages:
Linkedin Mini logo Thelansis Twitter Mini logoThelansis Facebook Mini logo

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Competitive Landscape

S. no Asset Company Stage
1 Venetoclax AbbVie Phase 1
2 Cyclophosphamide (Non-IMP) AvenCell Therapeutics Phase 1
3 IMGN632 ImmunoGen, Inc. Phase 2
4 CD123 Chongqing Precision Biotech Co., Ltd Phase 2
5 XmAb14045 Xencor, Inc. Phase 1
6 ELZONRIS® (Tagraxofusp) Stemline Therapeutics Phase 2

KOLs across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

COUNTRY No. Of KOLs
USA 17
GERMANY 4
UK 4
SPAIN 3
FRANCE 2
ITALY 3
JAPAN 3
CHINA 4

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Market Forecast

 

1.       Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) – Key Findings Summary

         1.1.    Clinical findings
                     1.1.1. Disease overview
                     1.1.2. Therapeutic practices
                     1.1.3. Future outlook
         1.2.    Commercial findings
                     1.2.1. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market scenario 2021
                     1.2.2. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market scenario 2025
                     1.2.3. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market scenario 2032

2.       Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Overview

         2.1.    Disease Introduction
         2.2.    Pathophysiology
         2.3.    Signs and Symptoms
         2.4.    Risk Factors
         2.5.    Etiology
         2.6.    Classification
         2.7.    Pathogenesis
         2.8.    Diagnosis
         2.9.    Complications
         2.10. Treatment Algorithm
                     2.10.1.    Treatment in US (guidelines)
                     2.10.2.    Treatment in EU-5 (guidelines)
                     2.10.3.    Treatment in Japan (guidelines)
                     2.10.4.    Treatment in China (guidelines)
         2.11. Treatment Goals for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
         2.12. Referral Patterns
                     2.12.1.    Referral Scenario in US
                     2.12.2.    Referral Scenario in EU-5
                     2.12.3.    Referral Scenario in Japan
                     2.12.4.    Referral Scenario in China
         2.13. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Prognosis
         2.14. Healthcare burden
                     2.14.1.    Healthcare burden in US
                     2.14.2.    Healthcare burden in EU-5
                     2.14.3.    Healthcare burden in Japan
                     2.14.4.    Healthcare burden in China
         2.15.  Unmet Needs in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) management
         2.16.  Market Opportunity for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
         2.17. KOL Comments on current and upcoming/expected treatment practices in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

3.       Epidemiology

         3.1.    Epidemiology Overview
         3.2.    Epidemiology by Geography
                     3.2.1.  Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in US (2021-2032)
                             3.2.1.1.              Incidence of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
                             3.2.1.2.              Diagnosed cases
                             3.2.1.3.              Treatable Patient Pool
                             3.2.1.4.              Epidemiology Trends
                     3.2.2.  Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in EU-5 (2021-2032)
                             3.2.2.1.              Incidence of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
                             3.2.2.2.              Diagnosed cases
                             3.2.2.3.              Treatable Patient Pool
                             3.2.2.4.              Epidemiology Trends
                     3.2.3.  Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in Japan (2021-2032)
                             3.2.3.1.              Incidence of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
                             3.2.3.2.              Diagnosed cases
                             3.2.3.3.              Treatable Patient Pool
                             3.2.3.4.              Epidemiology Trends
                     3.2.4.  Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in China (2021-2032)
                             3.2.4.1.              Incidence of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
                             3.2.4.2.              Diagnosed cases
                             3.2.4.3.              Treatable Patient Pool
                             3.2.4.4.              Epidemiology Trends
         3.3.    Epidemiology Trends (World-wide)

4.       Market Outlook

         4.1.    US Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Forecast 2021-2032
                     4.1.1. Market Progression (Futuristic)
                     4.1.2. Market Trends and Expectations
                             4.1.2.1.              Worst case scenario
                             4.1.2.2.              Base Case Scenario
                             4.1.2.3.              Best Case Scenario
                     4.1.3. Drivers and Barriers
         4.2.    UK Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Forecast 2021-2032
                     4.2.1. Market Progression (Futuristic)
                     4.2.2. Market Trends and Expectations
                             4.2.2.1.              Worst case scenario
                             4.2.2.2.              Base Case Scenario
                             4.2.2.3.              Best Case Scenario
                     4.2.3. Drivers and Barriers
         4.3.    France Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Forecast 2021-2032
                     4.3.1. Market Progression (Futuristic)
                     4.3.2. Market Trends and Expectations
                             4.3.2.1.              Worst case scenario
                             4.3.2.2.              Base Case Scenario
                             4.3.2.3.              Best Case Scenario
                     4.3.3. Drivers and Barriers
         4.4.    Germany Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Forecast 2021-2032
                     4.4.1. Market Progression (Futuristic)
                     4.4.2. Market Trends and Expectations
                             4.4.2.1.              Worst case scenario
                             4.4.2.2.              Base Case Scenario
                             4.4.2.3.              Best Case Scenario
                     4.4.3. Drivers and Barriers
         4.5.    Italy Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Forecast 2021-2032
                     4.5.1. Market Progression (Futuristic)
                     4.5.2. Market Trends and Expectations
                             4.5.2.1.              Worst case scenario
                             4.5.2.2.              Base Case Scenario
                             4.5.2.3.              Best Case Scenario
                     4.5.3. Drivers and Barriers
         4.6.    Spain Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Forecast 2021-2032
                     4.6.1. Market Progression (Futuristic)
                     4.6.2. Market Trends and Expectations
                             4.6.2.1.              Worst case scenario
                             4.6.2.2.              Base Case Scenario
                             4.6.2.3.              Best Case Scenario
                     4.6.3. Drivers and Barriers
         4.7.    Japan Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Forecast 2021-2032
                     4.7.1. Market Progression (Futuristic)
                     4.7.2. Market Trends and Expectations
                             4.7.2.1.              Worst case scenario
                             4.7.2.2.              Base Case Scenario
                             4.7.2.3.              Best Case Scenario
                     4.7.3. Drivers and Barriers
         4.8.    China Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Forecast 2021-2032
                     4.8.1. Market Progression (Futuristic)
                     4.8.2. Market Trends and Expectations
                             4.8.2.1.              Worst case scenario
                             4.8.2.2.              Base Case Scenario
                             4.8.2.3.              Best Case Scenario
                     4.8.3. Drivers and Barriers
         4.9.    Key Expected Milestones (world-wide) Impacting the Market

5.       Competitive Landscape

         5.1.    Pipeline Therapies Overview
                     5.1.1. Phase III Therapies
                                      5.1.1.1.                     Current Status
                                      5.1.1.2.                     Trial details, results
                                      5.1.1.3.                     Approval Timeline
                                      5.1.1.4.                     Likelihood of approval
                                      5.1.1.5.                     Expected Product Positioning
                             5.1.1.2.              All other Phase III Therapies …..
                             5.1.1.3.              Attribute Analysis of Phase III molecules
                     5.1.2.  Phase II and Phase I/II Therapies
                                      5.1.2.1.                     Current Status
                                      5.1.2.2.                     Trial details, results
                                      5.1.2.3.                     Approval Timelines
                     5.1.3. List of active Pre-clinical Therapies
                                      5.1.3.1.                     Status in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
                                      5.1.3.2.                     Company positioning
                             5.1.3.2.              All other pre-clinical therapies
                     5.1.4. List of Inactive/discontinued assets
                             5.1.4.1.              Business impact of discontinuations on current pipeline
                     5.1.5. Potential winners from Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Pipeline
                             5.1.5.1.              Potential Blockbusters across the pipeline

6.       Regulatory/Approval Scenario

         6.1.    Regulatory/Approval Framework in US
                     6.1.1. Policy Framework
                     6.1.2. Payer Expectations
         6.2.    Regulatory/Approval Framework in UK
                     6.2.1. Policy Framework
                     6.2.2. Payer Expectations
         6.3.    Regulatory/Approval Framework in France
                     6.3.1. Policy Framework
                     6.3.2. Payer Expectations
         6.4.    Regulatory/Approval Framework in Germany
                     6.4.1. Policy Framework
                     6.4.2. Payer Expectations
         6.5.    Regulatory/Approval Framework in Italy
                     6.5.1. Policy Framework
                     6.5.2. Payer Expectations
         6.6.    Regulatory/Approval Framework in Spain
                     6.6.1. Policy Framework
                     6.6.2. Payer Expectations
         6.7.       Regulatory/Approval Framework in Japan
                     6.7.1. Policy Framework
                     6.7.2. Payer Expectations
         6.8.       Regulatory/Approval Framework in China
                     6.8.1. Policy Framework
                     6.8.2. Payer Expectations

7.       Clinical Trial Assessment – Current and Future Paradigm

         7.1.    Distribution of Primary Endpoints across trials
         7.2.    Distribution of Secondary Endpoints across trials
         7.3.    Evolution and acceptance of surrogate endpoints
         7.4.    Key Investigator initiated trials
         7.5.    Attrition analysis
                     7.5.1. Suspended/Discontinued Assets
                     7.5.2. Failed Trials, Reasons and Business Impact
                     7.5.3. Terminated Trials, Reasons and Business Impact
                     7.5.4. Withdrawn Trials, Reasons and Business Impact
         7.6.    Trial enrollment scenario and challenges
         7.7.    Clinical Trial Guidance (across geographies)

8.       Thelansis Commentary

         8.1.    Key Unmet needs in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
         8.2.    Possible Best-case Clinical Trial Strategies
         8.3.    Possible Best Case Targeted Product Profile (TPP)
         8.4.    Possible Best-case Market positioning strategies
         8.5.    Possible Best-case Market Access Strategies
         8.6.    Possible Best-case LCM Strategies
         8.7.    Overall View on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market in Dollar Value

9.       Report Methodology

         9.1.    Secondary research
         9.2.    Primary research
         9.3.    Data collation
         9.4.    Insight Generation

10.   About Thelansis

         10.1.    Our Capabilities
         10.2.    Our Services
         10.3.    Our Contacts
         10.4.    Disclaimer